Close Menu
    What's Hot

    Credit Commercial de France Pension Scheme Completes Bulk Purchase Annuity Buy-In With Royal London

    July 23, 2026

    Smiths Industries Pension Scheme Completes Bulk Purchase Annuity Buy-In With M&G

    July 23, 2026

    End-Game Clarity Shaping UK Pension Risk Transfer Market but Large Schemes Still on the Sidelines

    July 22, 2026
    X (Twitter) LinkedIn
    Longevity & Mortality Investor
    • Home
    • Coverage
      1. Life Insurance Capital Solutions
      2. Life Insurance
      3. Longevity and Mortality Risk Transfer
      4. Mortality
      5. Secondary Life Markets
      6. View All

      Big Year of Growth for Life/Annuity Sidecar-Like Activity in 2025

      July 2, 2026

      Sixth Street To Become Majority Shareholder of Monument Re

      June 30, 2026

      Pacific Life Re Appoints Florence Durousseau as Head of Capital Solutions, Europe

      June 15, 2026

      Third Block Reinsurance Deal With Tokio Marine & Nichido Life for Pacific Life Re

      June 10, 2026

      Shaping the Future of Health Insurance Through Innovation and Analytics

      June 10, 2026

      Q&A: Dr Christoph Schmitt, Director, Insurance, Fitch Ratings

      May 28, 2026

      Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

      May 13, 2026

      US Annuity Sales Notch Tenth Consecutive $100bn+ Quarter

      May 11, 2026

      Credit Commercial de France Pension Scheme Completes Bulk Purchase Annuity Buy-In With Royal London

      July 23, 2026

      Smiths Industries Pension Scheme Completes Bulk Purchase Annuity Buy-In With M&G

      July 23, 2026

      End-Game Clarity Shaping UK Pension Risk Transfer Market but Large Schemes Still on the Sidelines

      July 22, 2026

      Q&A: Yona Chesner, Head of Pensions Investment, Cartwright Pension Trusts

      July 22, 2026

      Record Low Mortality Rates So Far in England and Wales in 2026

      July 9, 2026

      Organ Transplant Improvements Test Life Expectancy Assessment Models

      July 8, 2026

      The Pursuit of Everlasting Life Unlikely to Shift Actuarial Models

      June 10, 2026

      Pricing in the Unknown: Why Mortality Models Aren’t Ready for MCED Tests Just Yet

      April 9, 2026
      Litigation

      Litigation Update: Estate of Martha Barotz v. Wilmington Savings Fund Society, FSB, et al.

      July 22, 2026

      South Dakota Supreme Court Upholds Life Settlement Investor’s Right to Retain $10 Million Death Benefit

      July 22, 2026

      Optimism for Stronger Second Half in the Life Settlement Tertiary Market

      July 8, 2026

      US Life Insurers Embrace Securitised Credit as Demand for Yield and Diversification Grows but Hurdles Remain for Longevity-Linked Assets

      July 8, 2026

      Credit Commercial de France Pension Scheme Completes Bulk Purchase Annuity Buy-In With Royal London

      July 23, 2026

      Smiths Industries Pension Scheme Completes Bulk Purchase Annuity Buy-In With M&G

      July 23, 2026

      End-Game Clarity Shaping UK Pension Risk Transfer Market but Large Schemes Still on the Sidelines

      July 22, 2026
      Litigation

      Litigation Update: Estate of Martha Barotz v. Wilmington Savings Fund Society, FSB, et al.

      July 22, 2026
    • Events
    • Latest Issues

      Editor’s Letter – Volume 2, Issue 7, July 2026

      July 8, 2026

      Editor’s Letter – Volume 2, Issue 6, June 2026

      June 10, 2026

      Editor’s Letter – Volume 2, Issue 5, May 2026

      May 13, 2026

      Editor’s Letter – Volume 2, Issue 4, April 2026

      April 9, 2026

      Editor’s Letter – Volume 2, Issue 3, March 2026

      March 11, 2026
    • Contact Us
    Newsletter
    Longevity & Mortality Investor

    How Technology Is Transforming Medical Record Reviews in Life Settlements

    Secondary Life Markets November 12, 2025By Dan Sobolewski
    Share
    Twitter LinkedIn Email

    Within the life settlement industry, the medical record review has long remained one of the most resource-intensive and time-consuming stages of the process. Even as other aspects of the industry have adopted data-driven solutions, this particular function continues to depend heavily on manual review. Underwriters are often tasked with sorting through thousands of pages of unstructured, inconsistent, and redundant medical information, an endeavor that can delay transactions, increase costs, and limit deal flow. 

    Recent advancements in automation and artificial intelligence, however, are beginning to change this dynamic. The ability to interpret and structure medical data with greater accuracy and speed is reshaping how the industry approaches one of its most persistent bottlenecks. 

    The Enduring Bottleneck 

    Medical records form the evidentiary basis of every life settlement transaction. They inform life expectancy estimates, guide underwriting decisions, and influence valuations. Yet the format and inconsistency of these records often make the review process cumbersome. A single case file can exceed 10,000 pages and include a combination of faxes, handwritten notes, lab results, and scanned reports, often from multiple providers. 

    Reviewers must identify relevant diagnoses, medications, and procedures buried within this mass of information. The process demands a high level of expertise but is inherently repetitive. For years, industry professionals have described it as a “needle-in-a-haystack” exercise that consumes valuable time and introduces unnecessary friction into the transaction lifecycle. 

    At its core, the challenge lies not in the quality of the underwriting itself but in the inefficiency of the information pipeline. Medical data is designed for patient care, not for investment evaluation. Converting that data into an accessible, structured format remains a major obstacle to efficiency. 

    The Rise of Automation 

    Automation has already transformed several document-intensive industries, including insurance claims, legal discovery, and mortgage processing. The life settlement sector now finds itself on the cusp of a similar transition. 

    At its essence, automation in medical record review involves the use of algorithms to extract and classify relevant data while filtering out extraneous content. These systems leverage a combination of optical character recognition, natural language processing, and medical ontologies to recognize terminology, identify relationships among conditions, and present structured summaries that underwriters can review directly. 

    Importantly, this technology is not a replacement for human expertise but a complement to it. Automated tools handle the labor-intensive elements—scanning, categorizing, and highlighting key data—so that human underwriters can focus on interpretation, risk assessment, and judgment. The result is not mechanization but augmentation. 

    Benefits Across the Transaction Chain 

    The adoption of automation yields benefits across every level of the life settlement value chain. 

    • Reduced review timelines: Automated systems can condense weeks of manual work into days, accelerating underwriting and enabling greater throughput. 
    • Enhanced accuracy: Machines do not tire or lose concentration, which helps maintain consistent standards across large record sets. They also improve error detection by cross-referencing terms and recognizing anomalies that might escape human attention. 
    • Lower operational costs: Streamlining review processes decreases administrative overhead and reallocates skilled labor toward higher-value tasks. 
    • Improved transparency and compliance: Structured, auditable data outputs make it easier to document what information informed a decision, strengthening both regulatory and investor confidence. 
    • Faster outcomes for policyowners: Shorter processing times mean policyowners receive offers sooner, improving the overall market experience. 

    Once medical data has been digitized and standardized, its value extends far beyond underwriting. Structured datasets enable richer analytics, predictive modeling, and performance benchmarking across portfolios. Investors and providers can analyze trends over time, while institutions can adopt more consistent valuation frameworks. 

    Implementation and Oversight 

    While the benefits of automation are clear, effective implementation requires thoughtful execution. Each organization in the life settlement ecosystem, whether a provider, broker, or institutional investor, has distinct operational workflows. Successful adoption therefore depends on integrating automation in ways that respect these variations rather than replacing existing infrastructure entirely. 

    Security remains paramount. Medical records contain some of the most sensitive categories of personal information, and their handling must meet the strictest standards of data protection and compliance, including HIPAA and SOC 2. Beyond compliance, there must also be careful attention to human oversight. 

    The most effective approaches employ a hybrid model in which technology handles the data extraction, classification, and organization, while human reviewers validate and interpret the output. This approach maintains accuracy while delivering significant gains in speed and consistency. 

    The Broader Outlook 

    As automation becomes more sophisticated, its impact on the life settlement industry will extend well beyond medical record review. Structured medical data could enable faster underwriting models, facilitate portfolio analytics, and support continuous monitoring of life expectancy assumptions. 

    In time, the same underlying technologies could allow for more dynamic risk assessment and greater liquidity in the secondary market. As standardized data becomes the norm, investors will be able to compare portfolios more effectively, reinsurers will assess exposure more accurately, and regulators will have greater clarity into underlying assumptions and practices. 

    These developments would represent a significant maturation of the asset class. What was once a largely manual, paper-based process could evolve into a transparent, data-driven marketplace. 

    Conclusion 

    The life settlement industry stands at an important inflection point. The fundamental challenge of managing unstructured medical data has persisted for decades, but the tools now exist to address it in a meaningful way. Automation and intelligent data processing are not theoretical improvements; they are practical, measurable solutions that can reshape the economics and efficiency of life settlements. 

    The firms that adopt these technologies early are likely to set new standards for speed, accuracy, and transparency. Ultimately, the ability to convert medical records into structured, decision-ready insights may determine which organizations lead the industry’s next phase of growth. 

    Dan Sobolewski is CEO at ProtectFlow 

    Any views expressed in this article are those of the author(s) and may not necessarily represent those of Longevity & Mortality Investor or its publisher, the European Life Settlement Association

    2025 - November Commentary Life Settlements Longevity Risk Volume 1 Issue 2 – November 2025
    Share. Twitter LinkedIn Email

    Related Posts

    Credit Commercial de France Pension Scheme Completes Bulk Purchase Annuity Buy-In With Royal London

    July 23, 2026By LMI Newsdesk

    Smiths Industries Pension Scheme Completes Bulk Purchase Annuity Buy-In With M&G

    July 23, 2026By LMI Newsdesk

    End-Game Clarity Shaping UK Pension Risk Transfer Market but Large Schemes Still on the Sidelines

    July 22, 2026By Mark McCord
    Litigation

    Litigation Update: Estate of Martha Barotz v. Wilmington Savings Fund Society, FSB, et al.

    July 22, 2026By Greg Winterton
    Latest Issue

    Optimism for Stronger Second Half in the Life Settlement Tertiary Market

    July 8, 2026

    Organ Transplant Improvements Test Life Expectancy Assessment Models

    July 8, 2026

    US Life Insurers Embrace Securitised Credit as Demand for Yield and Diversification Grows but Hurdles Remain for Longevity-Linked Assets

    July 8, 2026

    Passage of UK Pension Schemes Act Seen Boosting Size of DB Superfund Market

    June 24, 2026
    Ad

    Where Longevity and Mortality Meet the Markets
    ISSN 2978-5219

    X (Twitter) LinkedIn
    Coverage
    • Life Insurance Capital Solutions
    • Life Insurance
    • Longevity and Mortality Risk Transfer
    • Mortality Risk
    • Secondary Life Markets
    More Info
    • Home
    • About Us
    • Contact Us
    • Guest Articles
    • Submit Story Idea
    Our Newsletter
    Get the latest industry news, commentary and events from the Longevity & Mortality Investor directly into your inbox. Why not sign up today?

    © 2026 Longevity & Mortality Investor. Website by Kavells.
    • Sitemap
    • Privacy Policy
    • Copyright Notice
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.